Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer

This study tests whether adding immunotherapy (toripalimab, which activates the immune system) and targeted radiation (SBRT—high-precision, high-dose radiation to specific tumors) can help women with triple-negative breast cancer whose tumors did not shrink enough after initial standard chemotherapy before surgery. Triple-negative breast cancer is a harder-to-treat type that does not respond to hormone-based treatments. **You may be eligible if...** - You are a woman between 18 and 75 years old with newly diagnosed triple-negative breast cancer - Your cancer is stage II or III - You completed 2 cycles of standard chemotherapy (taxane-based) but your tumor did not shrink (stable or growing on imaging) - You are in good physical condition (ECOG 0–1) - Your organ function is adequate and you do not have HIV or active hepatitis **You may NOT be eligible if...** - You have inflammatory breast cancer - You have had another cancer requiring treatment in the past 3 years - You have an active autoimmune disease or are on high-dose steroids - You have serious heart disease - You have had prior radiation to the breast or chest - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.